Symbols / GOSS $0.47 +3.53%
GOSS Chart
About
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 109.27M |
| Enterprise Value | 128.20M | Income | -156.16M | Sales | 44.05M |
| Book/sh | -0.36 | Cash/sh | 0.78 | Dividend Yield | — |
| Payout | 0.00% | Employees | 144 | IPO | — |
| P/E | — | Forward P/E | -0.93 | PEG | — |
| P/S | 2.48 | P/B | -1.33 | P/C | — |
| EV/EBITDA | -0.84 | EV/Sales | 2.91 | Quick Ratio | 3.06 |
| Current Ratio | 3.28 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.69 | EPS next Y | -0.51 | EPS Growth | — |
| Revenue Growth | 40.20% | Earnings | 2026-03-18 | ROA | -34.25% |
| ROE | — | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -3.13% | Profit Margin | 0.00% | Shs Outstand | 231.46M |
| Shs Float | 207.91M | Short Float | 15.95% | Short Ratio | 1.37 |
| Short Interest | — | 52W High | 3.87 | 52W Low | 0.33 |
| Beta | 2.11 | Avg Volume | 14.49M | Volume | 3.46M |
| Target Price | $3.69 | Recom | Buy | Prev Close | $0.46 |
| Price | $0.47 | Change | 3.53% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.69
Mean price target
2. Current target
$0.47
Latest analyst target
3. DCF / Fair value
$-6.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.47
Low
$0.30
High
$15.00
Mean
$3.69
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-06 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2026-03-05 | main | Oppenheimer | Outperform → Outperform | $3 |
| 2026-02-24 | down | Wedbush | Outperform → Neutral | $1 |
| 2026-02-24 | down | Barclays | Overweight → Underweight | $0 |
| 2026-02-24 | down | Leerink Partners | Outperform → Market Perform | $1 |
| 2026-01-28 | init | Barclays | — → Overweight | $9 |
| 2026-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-09-11 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-09-10 | up | UBS | Neutral → Buy | $9 |
| 2025-08-06 | main | Wedbush | Outperform → Outperform | $5 |
| 2025-07-14 | init | Scotiabank | — → Sector Outperform | $11 |
| 2025-05-16 | main | Goldman Sachs | Buy → Buy | $8 |
| 2025-05-16 | reit | Wedbush | Outperform → Outperform | $4 |
| 2025-04-17 | main | Goldman Sachs | Buy → Buy | $7 |
| 2025-03-14 | reit | Wedbush | Outperform → Outperform | $4 |
| 2025-01-30 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-11 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-09-17 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-30 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-13 | reit | Wedbush | Outperform → Outperform | $4 |
- Here's Why Gossamer Bio (GOSS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance hu, 26 Feb 2026 08
- GOSS Technical Analysis | Trend, Signals & Chart Patterns | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill hu, 12 Mar 2026 07
- Lung disease drug helps sicker patients walk farther but misses main trial goal - Stock Titan Mon, 23 Feb 2026 08
- Gossamer Bio stock tumbles 80% on trial miss - Investing.com Mon, 23 Feb 2026 08
- $GOSS stock is down 12% today. Here's what we see in our data. - Quiver Quantitative ue, 23 Dec 2025 08
- GOSS Gossamer Bio NASDAQ $0.56 10 Mar 2026: Pre-market ahead of Mar 12 earnings - Meyka ue, 10 Mar 2026 11
- GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP - PR Newswire Wed, 04 Mar 2026 08
- Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits Mon, 23 Feb 2026 16
- Gossamer Bio Inc Stock (ISIN: US38198T1034) Surges on Clinical Momentum and Analyst Optimism - AD HOC NEWS Fri, 13 Mar 2026 12
- Gossamer Bio, Inc.'s (NASDAQ:GOSS) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st hu, 22 Jan 2026 08
- GOSS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan Sat, 07 Mar 2026 15
- Gossamer Bio, Inc. (GOSS) Stock Jumps 18% on FDA Updates and Seralutinib Progress - Yahoo Finance ue, 23 Sep 2025 07
- How The Gossamer Bio (GOSS) Story Is Shifting After PROSERA And New Street Valuations - Yahoo Finance Mon, 09 Mar 2026 07
- A Look At Gossamer Bio (GOSS) Valuation After Barclays Strong Buy Upgrade And Rising Institutional Ownership - Yahoo Finance Mon, 16 Feb 2026 08
- Oppenheimer Confident in Positive PROSERA Trial Readout in February 2026 for Gossamer Bio (GOSS) - Yahoo Finance Mon, 15 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 280000 | — | — | Stock Award(Grant) at price 0.00 per share. | HASNAIN FAHEEM | Chief Executive Officer | — | 2026-01-02 00:00:00 | D |
| 1 | 115750 | — | — | Stock Award(Grant) at price 0.00 per share. | GIRAUDO BRYAN M. | Chief Operating Officer | — | 2026-01-02 00:00:00 | D |
| 2 | 84500 | — | — | Stock Award(Grant) at price 0.00 per share. | PETERSON CARYN | Officer | — | 2026-01-02 00:00:00 | D |
| 3 | 93750 | — | — | Stock Award(Grant) at price 0.00 per share. | ARANDA RICHARD | Officer | — | 2026-01-02 00:00:00 | D |
| 4 | 84500 | — | — | Stock Award(Grant) at price 0.00 per share. | CHRISTIAN WAAGE | Officer | — | 2026-01-02 00:00:00 | D |
| 5 | 93750 | — | — | Stock Award(Grant) at price 0.00 per share. | SMITH ROBERT PAUL JR | Officer | — | 2026-01-02 00:00:00 | D |
| 6 | 437500 | — | — | Stock Award(Grant) at price 0.00 per share. | HASNAIN FAHEEM | Chief Executive Officer | — | 2025-10-01 00:00:00 | D |
| 7 | 181250 | — | — | Stock Award(Grant) at price 0.00 per share. | GIRAUDO BRYAN M. | Chief Operating Officer | — | 2025-10-01 00:00:00 | D |
| 8 | 125000 | — | — | Stock Award(Grant) at price 0.00 per share. | PETERSON CARYN | Officer | — | 2025-10-01 00:00:00 | D |
| 9 | 162500 | — | — | Stock Award(Grant) at price 0.00 per share. | ARANDA RICHARD | Officer | — | 2025-10-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -39.97M | -151.92M | -211.00M | -209.32M |
| TotalUnusualItems | 0.00 | -10.00M | -65.00K | -75.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -10.00M | -65.00K | -75.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -56.53M | -179.82M | -229.38M | -234.00M |
| ReconciledDepreciation | 4.15M | 4.38M | 4.43M | 5.17M |
| EBITDA | -39.97M | -161.92M | -211.07M | -209.40M |
| EBIT | -44.12M | -166.31M | -215.50M | -214.56M |
| NetInterestIncome | -9.74M | -11.51M | -12.30M | -18.68M |
| InterestExpense | 11.52M | 13.51M | 13.88M | 19.44M |
| InterestIncome | 1.78M | 2.00M | 1.58M | 761.00K |
| NormalizedIncome | -56.53M | -169.82M | -229.31M | -233.93M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -56.53M | -179.82M | -229.38M | -234.00M |
| TotalExpenses | 174.62M | 173.76M | 218.53M | 216.05M |
| TotalOperatingIncomeAsReported | -59.92M | -183.76M | -218.59M | -216.12M |
| DilutedAverageShares | 226.23M | 152.62M | 84.57M | 74.84M |
| BasicAverageShares | 226.23M | 152.62M | 84.57M | 74.84M |
| DilutedEPS | -0.25 | -1.18 | -2.71 | -3.13 |
| BasicEPS | -0.25 | -1.18 | -2.71 | -3.13 |
| DilutedNIAvailtoComStockholders | -56.53M | -179.82M | -229.38M | -234.00M |
| NetIncomeCommonStockholders | -56.53M | -179.82M | -229.38M | -234.00M |
| NetIncome | -56.53M | -179.82M | -229.38M | -234.00M |
| NetIncomeIncludingNoncontrollingInterests | -56.53M | -179.82M | -229.38M | -234.00M |
| NetIncomeContinuousOperations | -56.53M | -179.82M | -229.38M | -234.00M |
| TaxProvision | 893.00K | 0.00 | 0.00 | |
| PretaxIncome | -55.63M | -179.82M | -229.38M | -234.00M |
| OtherIncomeExpense | 14.02M | 5.46M | 1.45M | 724.00K |
| OtherNonOperatingIncomeExpenses | 14.02M | 15.46M | 1.51M | 799.00K |
| SpecialIncomeCharges | 0.00 | -10.00M | -65.00K | -75.00K |
| OtherSpecialCharges | 10.00M | 65.00K | 75.00K | |
| NetNonOperatingInterestIncomeExpense | -9.74M | -11.51M | -12.30M | -18.68M |
| InterestExpenseNonOperating | 11.52M | 13.51M | 13.88M | 19.44M |
| InterestIncomeNonOperating | 1.78M | 2.00M | 1.58M | 761.00K |
| OperatingIncome | -59.92M | -173.76M | -218.53M | -216.05M |
| OperatingExpense | 174.62M | 173.76M | 218.53M | 216.05M |
| ResearchAndDevelopment | 138.49M | 135.30M | 170.92M | 170.27M |
| SellingGeneralAndAdministration | 36.13M | 38.45M | 47.61M | 45.78M |
| GeneralAndAdministrativeExpense | 36.13M | 38.45M | 47.61M | 45.78M |
| OtherGandA | 36.13M | 38.45M | 47.61M | 45.78M |
| TotalRevenue | 114.70M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 114.70M | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 226.60M | 225.41M | 94.42M | 75.75M |
| ShareIssued | 226.60M | 225.41M | 94.42M | 75.75M |
| NetDebt | 151.45M | 176.91M | 107.34M | |
| TotalDebt | 202.88M | 212.46M | 225.74M | 185.24M |
| TangibleBookValue | 29.49M | 62.77M | 12.08M | 121.46M |
| InvestedCapital | 227.01M | 271.79M | 231.39M | 300.58M |
| WorkingCapital | 264.88M | 254.92M | 212.65M | 291.92M |
| NetTangibleAssets | 29.49M | 62.77M | 12.08M | 121.46M |
| CapitalLeaseObligations | 5.36M | 3.45M | 6.43M | 6.12M |
| CommonStockEquity | 29.49M | 62.77M | 12.08M | 121.46M |
| TotalCapitalization | 227.01M | 260.17M | 219.77M | 300.58M |
| TotalEquityGrossMinorityInterest | 29.49M | 62.77M | 12.08M | 121.46M |
| StockholdersEquity | 29.49M | 62.77M | 12.08M | 121.46M |
| GainsLossesNotAffectingRetainedEarnings | 1.19M | -350.00K | -574.00K | 45.00K |
| OtherEquityAdjustments | 1.19M | -350.00K | -574.00K | 45.00K |
| RetainedEarnings | -1.27B | -1.21B | -1.03B | -811.53M |
| AdditionalPaidInCapital | 1.30B | 1.28B | 1.04B | 932.94M |
| CapitalStock | 23.00K | 23.00K | 10.00K | 8.00K |
| CommonStock | 23.00K | 23.00K | 10.00K | 8.00K |
| TotalLiabilitiesNetMinorityInterest | 285.80M | 249.15M | 260.37M | 222.19M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 240.79M | 197.55M | 211.14M | 182.34M |
| NonCurrentDeferredLiabilities | 38.87M | 0.00 | ||
| NonCurrentDeferredRevenue | 38.87M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 201.92M | 197.55M | 211.14M | 182.34M |
| LongTermCapitalLeaseObligation | 4.40M | 144.00K | 3.45M | 3.22M |
| LongTermDebt | 197.52M | 197.41M | 207.70M | 179.12M |
| CurrentLiabilities | 45.01M | 51.60M | 49.23M | 39.86M |
| CurrentDeferredLiabilities | 17.05M | 0.00 | ||
| CurrentDeferredRevenue | 17.05M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 961.00K | 14.91M | 14.60M | 2.90M |
| CurrentCapitalLeaseObligation | 961.00K | 3.30M | 2.98M | 2.90M |
| CurrentDebt | 11.61M | 11.61M | ||
| OtherCurrentBorrowings | 11.61M | 11.61M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.99M | 10.29M | 13.53M | 11.92M |
| PayablesAndAccruedExpenses | 15.00M | 26.39M | 21.10M | 25.04M |
| CurrentAccruedExpenses | 12.69M | 20.86M | 19.64M | 21.80M |
| InterestPayable | 833.00K | 968.00K | 1.06M | 1.07M |
| Payables | 2.32M | 5.53M | 1.46M | 3.24M |
| AccountsPayable | 2.32M | 5.53M | 1.46M | 3.24M |
| TotalAssets | 315.29M | 311.92M | 272.45M | 343.66M |
| TotalNonCurrentAssets | 5.40M | 5.40M | 10.57M | 11.88M |
| OtherNonCurrentAssets | 283.00K | 618.00K | 680.00K | 1.08M |
| NetPPE | 5.12M | 4.78M | 9.89M | 10.80M |
| AccumulatedDepreciation | -183.00K | -5.43M | -6.11M | -4.28M |
| GrossPPE | 5.30M | 10.21M | 16.00M | 15.08M |
| Leases | 0.00 | 2.56M | 2.56M | 2.56M |
| ConstructionInProgress | 0.00 | 83.00K | 0.00 | |
| OtherProperties | 5.30M | 6.38M | 12.01M | 11.16M |
| MachineryFurnitureEquipment | 0.00 | 1.27M | 1.35M | 1.35M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 309.89M | 306.52M | 261.88M | 331.78M |
| OtherCurrentAssets | 10.03M | 10.09M | 6.20M | 6.50M |
| RestrictedCash | 0.00 | 64.00K | ||
| PrepaidAssets | 6.20M | 6.50M | ||
| Receivables | 5.34M | 0.00 | ||
| OtherReceivables | 5.34M | |||
| CashCashEquivalentsAndShortTermInvestments | 294.52M | 296.43M | 255.68M | 325.22M |
| OtherShortTermInvestments | 248.44M | 264.32M | 143.71M | 141.81M |
| CashAndCashEquivalents | 46.07M | 32.11M | 111.97M | 183.40M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.47M | -159.16M | -187.51M | -190.51M |
| RepaymentOfDebt | -12.58M | -11.61M | -5.81M | 0.00 |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 0.00 | 201.32M | 119.95M | 0.00 |
| CapitalExpenditure | -475.00K | -1.62M | ||
| InterestPaidSupplementalData | 10.56M | 12.29M | 12.71M | 12.74M |
| EndCashPosition | 46.07M | 32.11M | 111.97M | 183.47M |
| BeginningCashPosition | 32.11M | 111.97M | 183.47M | 486.62M |
| EffectOfExchangeRateChanges | -102.00K | 110.00K | -517.00K | -165.00K |
| ChangesInCash | 14.07M | -79.97M | -70.98M | -302.99M |
| FinancingCashFlow | -11.49M | 190.15M | 117.09M | 3.33M |
| CashFlowFromContinuingFinancingActivities | -11.49M | 190.15M | 117.09M | 3.33M |
| ProceedsFromStockOptionExercised | 1.09M | 444.00K | 2.95M | 3.33M |
| NetCommonStockIssuance | 0.00 | 201.32M | 119.95M | 0.00 |
| CommonStockIssuance | 0.00 | 201.32M | 119.95M | 0.00 |
| NetIssuancePaymentsOfDebt | -12.58M | -11.61M | -5.81M | 0.00 |
| NetLongTermDebtIssuance | -12.58M | -11.61M | -5.81M | 0.00 |
| LongTermDebtPayments | -12.58M | -11.61M | -5.81M | 0.00 |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | 29.02M | -110.97M | -1.03M | -117.43M |
| CashFlowFromContinuingInvestingActivities | 29.02M | -110.97M | -1.03M | -117.43M |
| NetInvestmentPurchaseAndSale | 29.02M | -110.97M | -560.00K | -115.81M |
| SaleOfInvestment | 523.80M | 330.70M | 237.50M | 36.23M |
| PurchaseOfInvestment | -494.78M | -441.67M | -238.06M | -152.03M |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -65.00K | -75.00K |
| PurchaseOfIntangibles | 0.00 | 0.00 | -65.00K | -75.00K |
| NetPPEPurchaseAndSale | 0.00 | 0.00 | -410.00K | -1.55M |
| PurchaseOfPPE | 0.00 | 0.00 | -410.00K | -1.55M |
| OperatingCashFlow | -3.47M | -159.16M | -187.03M | -188.89M |
| CashFlowFromContinuingOperatingActivities | -3.47M | -159.16M | -187.03M | -188.89M |
| ChangeInWorkingCapital | 39.46M | -14.84M | -4.46M | 774.00K |
| ChangeInOtherWorkingCapital | 55.92M | 1.62M | -278.00K | |
| ChangeInOtherCurrentLiabilities | -3.39M | -2.98M | -2.72M | -3.58M |
| ChangeInOtherCurrentAssets | 335.00K | 62.00K | 400.00K | -53.00K |
| ChangeInPayablesAndAccruedExpense | -8.13M | -8.03M | -2.43M | 1.78M |
| ChangeInAccruedExpense | -6.48M | -12.02M | -621.00K | 6.20M |
| ChangeInInterestPayable | -135.00K | -97.00K | -1.00K | -28.00K |
| ChangeInPayable | -1.66M | 3.99M | -1.81M | -4.43M |
| ChangeInAccountPayable | -1.66M | 3.99M | -1.81M | -4.43M |
| ChangeInPrepaidAssets | 62.00K | -3.89M | 296.00K | 2.63M |
| ChangeInReceivables | -5.34M | 0.00 | 0.00 | |
| OtherNonCashItems | 1.09M | 11.32M | 1.23M | 6.81M |
| StockBasedCompensation | 20.62M | 28.52M | 42.55M | 32.01M |
| AmortizationOfSecurities | -13.06M | -9.45M | -1.41M | 339.00K |
| DepreciationAmortizationDepletion | 4.15M | 4.38M | 4.43M | 5.17M |
| DepreciationAndAmortization | 4.15M | 4.38M | 4.43M | 5.17M |
| Depreciation | 4.15M | 4.38M | 4.43M | 5.17M |
| OperatingGainsLosses | 806.00K | 726.00K | 20.00K | |
| GainLossOnSaleOfPPE | 806.00K | 726.00K | 0.00 | 20.00K |
| NetIncomeFromContinuingOperations | -56.53M | -179.82M | -229.38M | -234.00M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GOSS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|